Want to see MDGL full AI Analyst Report?
MDGL Stock Chart & Stats
$512.16
$10.45(1.92%)
At close: 4:00 PM EDT
$512.16
$10.45(1.92%)
Day’s Range― - ―
52-Week Range$393.61 - $615.00
Previous CloseN/A
Volume138.02K
Average Volume (3M)260.03K
Market Cap
$10.39B
Enterprise Value$15.16B
Total Cash (Recent Filing)$838.75M
Total Debt (Recent Filing)$347.75M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Oct 29, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.89
Shares Outstanding23,104,126
10 Day Avg. Volume326,320
30 Day Avg. Volume260,028
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)21.68
Price to Sales (P/S)13.63
P/FCF Ratio-68.75
Enterprise Value/Market Cap1.46
Enterprise Value/Revenue11.81
Enterprise Value/Gross Profit12.91
Enterprise Value/Ebitda-51.90
Forecast
1Y Price Target
$683.67Price Target Upside33.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-6.02
Revenue Forecast (FY)$1.52B
Bulls Say, Bears Say
Bulls Say
Rapid Rezdiffra AdoptionRezdiffra is demonstrating strong commercial traction, with rapid sales growth and a patient base that more than doubled year over year. Broad access, prescriber depth, adherence, and continued patient additions support a durable revenue expansion opportunity over the coming quarters.
Attractive Product EconomicsThe combination of substantial commercial revenue and exceptionally high gross margins indicates attractive unit economics for Rezdiffra. If the company can moderate commercial and research spending as sales scale, these economics provide a foundation for eventual operating leverage and stronger profitability.
Protected MASH Growth PlatformLong-dated intellectual-property protection supports Rezdiffra’s ability to remain a durable commercial foundation, while the expanding MASH pipeline creates avenues to broaden the franchise. Planned combination studies and additional assets could deepen the company’s market position over time.
Bears Say
Persistent Losses And Cash BurnDespite the revenue ramp, Madrigal has not yet converted commercialization into positive operating or free cash flow. Continued cash consumption can restrict funding flexibility and may require the company to rely on its available resources until sales growth sufficiently exceeds operating and development costs.
Heavy Operating InvestmentMadrigal is investing heavily in commercial expansion, endocrinology coverage, marketing, and pipeline development while still reporting losses. These costs may support future growth, but their continued increase raises the execution burden and delays the point at which strong gross margins translate into sustainable operating profitability.
Limited European ContributionEuropean launches and approvals have not yet translated into meaningful revenue because reimbursement access remains unresolved. This limits geographic diversification in the near term and leaves the business more dependent on continued U.S. execution while international market access develops more slowly than the product rollout.
Madrigal Pharmaceuticals News
MDGL FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest stock price was $393.61 and its highest was $615.00 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Madrigal Pharmaceuticals Inc’s market cap is $10.39B.
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is Oct 29, 2026 which is in 9 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Jul 30, 2026. The company reported -$1.99 earnings per share for the quarter, beating the consensus estimate of -$2.677 by $0.687.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -0.86.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 23,104,126 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$1.99 in its last earnings report, beating expectations of -$2.677. Following the earnings report the stock price went down -9.832%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MDGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$683.67 (33.49% Upside)
$683.67 (33.49% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 71%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 89.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.72%
12-Months-Change
Fundamentals
Return on Equity
-56.65%
Trailing 12-Months
Asset Growth
22.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
MDGL Company Deck
MDGL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive, driven by 71% year-over-year net sales growth, a patient base that more than doubled, progress past 50,000 patients, expanding market opportunity, encouraging real-world and clinical data, strengthened intellectual property, and a rapidly advancing pipeline. The main negatives were higher operating costs, a wider net loss, lower cash compared with year-end, negligible near-term European contribution due to reimbursement challenges, and continued uncertainty around the precise timing and event-rate dynamics of the F4-C trial. Highlights significantly outweighed the lowlights.View all MDGL earnings summariesMDGL Stock 12 Month Forecast
Average Price Target
$683.67
▲(33.49% Upside)
Technical Analysis
Exelixis
―
Ionis Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Roivant Sciences
―
Ownership Overview
18.08% Insiders
25.13% Mutual Funds
0.18% Other Institutional Investors
43.82% Public Companies and
Individual Investors